Does CMV reactivation cause functional impairment of CMV specific CD4+ T-cells? The potential for valaciclovir to prevent CMV-mediated adverse modulation of the immune system in patients with ANCA-associated vasculitis - CMV modulation of the immune system in ANCA-associated vasculitis - v1

niversity of Birmingham0 个研究点目标入组 50 人开始时间: 2012年10月10日最近更新: 2012年12月3日

适应症

试验速览

暂无简介。

•Documented diagnosis of ANCA associated vasculitis
•In stable remission (no documented clinical disease activity) for at least 6 months prior to entry.
•On maintenance immunosuppression with maximum 2 agents.
•Documented evidence of CMV infection.
•Documentation that female patients of child bearing age are not pregnant.
•Written informed consent for study participation
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 25
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 25

•Severe chronic kidney disease (Stage 5).
•Other significant chronic infection (HIV, HBV, HCV, TB).
•B-cell or T-cell depleting therapy within 12 months.
•Treatment with anti-CMV therapies in last month
•Underlying medical conditions, which in the opinion of the Investigator place the patient at unacceptably high risk for participating in the study.
•Inability to fully or appropriately participate in the study.

发起方